Clinical Trials Logo

SARS-CoV Infection clinical trials

View clinical trials related to SARS-CoV Infection.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04853134 Withdrawn - Covid19 Clinical Trials

Proxalutamide Treatment for COVID-19 Female Outpatients

Start date: November 1, 2020
Phase: Phase 3
Study type: Interventional

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

NCT ID: NCT04739449 Withdrawn - Covid19 Clinical Trials

'4C' Intervention to Reduce SARS-CoV-2 (Covid-19) Transmission

Start date: December 4, 2021
Phase: N/A
Study type: Interventional

Nursing homes have long faced special challenges in implementing effective infection prevention programs, including limited resources and diagnostic challenges in a frail functionally disabled long-stay population. Advancing our understanding of the transmission of SARS-CoV-2 within these facilities for vulnerable populations deserves urgent and further investigation. Environmental contamination with SARS-CoV-2 that is reported in limited studies highlights the potential importance of transmission between patients, their environment, and healthcare providers via direct and indirect contact. This study seeks to characterize the epidemiology of SARS-CoV- 2 in the NH patient room environment over time and the risk of transmission to near and far environments, with the explicit intent of developing integrated, simple COVID-19 infection prevention strategies that can be reported to and implemented throughout other nursing homes and long-term care facilities.

NCT ID: NCT04684550 Withdrawn - Covid19 Clinical Trials

Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)

Start date: February 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The pandemic caused by SARS-CoV-2 is a global emergency present in 6 continents including 66 countries, incurring a shortage of effective and safe therapeutic alternatives that can contribute to reducing the risk of contamination, as well as helping to reduce the viral load of the positive patient. This requires a coordinated, effective and immediate action on the part of governments, companies, academic entities and even at the individual level. In the search for new therapeutic and prevention alternatives, the application of hypochlorous acid (HClO) to the nasal mucosa is proposed, a broad-spectrum and fast-acting antimicrobial solution, whose safety has been proven in preclinical trials. The efficacy of HClO has been tested against enveloped and non-enveloped viruses, reducing virus particles without affecting human cells. This solution could contribute to reducing the viral load and the risk of contamination of patients and professionals. This could have an impact on controlling the COVID-19 pandemic.

NCT ID: NCT04651387 Withdrawn - SARS-CoV Infection Clinical Trials

Efficacy and Safety of Ozonised Oil (HOO) in COVID-19 Patients

HOO-COVID
Start date: July 2021
Phase: N/A
Study type: Interventional

The anti-viral efficacy of ozone against RNA viruses is already established. Ozone gas have been already proposed as possible therapy for Covid-19 infection with insofar limited success. The development of ozonized oil (HOO) solved this problems making ozone highly stable and bioavailable due to its bound with the lipid carrier. HOO administration is totally noninvasive occurring by oral administration of pills or as nasal spray. HOO regimen could be proposed as complimentary therapeutic treatment for Covid-19 infection, without the need of any modifications of the established standard therapeutic protocols. This complimentary treatment, could be helpful to (a) decrease the severity of the diseases lowering the number of Covid-19 patients requiring high-intensity therapies; (b) fasten qPCR negativization after disease and time-span of hospital recovery. The objective of this study is to investigates the effectiveness of combined use of "HOO capsules" and "HOO oropharyngeal and nasal spray" as a therapeutic supplement in the treatment of patients with confirmed COVID-19, who are moderately ill.

NCT ID: NCT04573634 Withdrawn - Covid19 Clinical Trials

A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition

START
Start date: May 15, 2020
Phase:
Study type: Observational

The co-primary objectives of this study are to: 1. Determine and compare the COVID-19 antibody positivity rate in health care workers and patients without a known COVID-19 infection 2. Determine if PCR negativity for COVID-19 early in quarantine predicts negativity at Day 14 in quarantining individuals

NCT ID: NCT04489628 Withdrawn - SARS-CoV Infection Clinical Trials

Tele-health Enabled Clinical Trial for COVID-19

Start date: August 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the efficacy of high dose Vitamin D (an over-the-counter nutritional supplement) in preventing immune-related complications in outpatients with confirmed SARS-CoV-2 infection.

NCT ID: NCT04473183 Withdrawn - Covid19 Clinical Trials

Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota

Start date: July 21, 2020
Phase:
Study type: Observational

The purpose of this epidemiologic study is to estimate the prevalence and incidence of anti-SARS-CoV-2 antibodies in at-risk, exposed, affected populations. The study will also estimate the risk of SARS-CoV-2 exposure in target population.

NCT ID: NCT04443868 Withdrawn - SARS-CoV Infection Clinical Trials

Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

Start date: January 2021
Phase: Phase 2
Study type: Interventional

This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.

NCT ID: NCT04334629 Withdrawn - Coronavirus Clinical Trials

LIBERATE Trial in COVID-19

LIBERATE
Start date: May 26, 2020
Phase: Phase 4
Study type: Interventional

The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.